Inegy

Simvastatin, the active ingredient in Inegy, is a statin (HMG‑CoA reductase inhibitor) presented as an oral tablet for systemic use. It lowers elevated cholesterol levels and is combined with ezetimibe to treat hypercholesterolemia, mixed dyslipidemia, and heterozygous familial hypercholesterolemia in adult patients at risk of cardiovascular disease and in patients with established atherosclerotic disease.

GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory conformity, and reliable distribution across diverse markets.

Inegy, a fixed‑dose combination of a statin and a cholesterol absorption inhibitor, is used to manage disorders of lipid metabolism.

Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol and total cholesterol, helping achieve target lipid levels in patients with primary or secondary hypercholesterolemia. Mixed dyslipidemia: lowers LDL‑cholesterol and triglycerides while modestly increasing high‑density lipoprotein (HDL) cholesterol, improving the overall lipid profile in patients with combined lipid abnormalities. Heterozygous familial hypercholesterolemia: provides additional LDL‑cholesterol reduction when statin monotherapy does not achieve sufficient control in genetically predisposed individuals.

Inegy may cause a range of adverse reactions, which are generally categorized by frequency and clinical significance.

Common Side Effects: - Headache: mild to moderate intensity. - Gastrointestinal discomfort: including nausea, abdominal pain, or diarrhoea. - Myalgia: muscle aches without weakness. - Elevated liver enzymes: transient increases in ALT or AST. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to renal failure. - Acute liver injury: marked elevation of hepatic enzymes or jaundice. - Severe allergic reactions: such as angio‑edema or anaphylaxis. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Myopathy with weakness: muscle pain accompanied by reduced strength.

When prescribing Inegy, clinicians should observe several precautionary measures to ensure patient safety. Baseline liver assessment: obtain hepatic function tests before initiating therapy. Muscle symptom monitoring: advise patients to report unexplained muscle pain, tenderness or weakness. Avoid in active liver disease: contraindicated in patients with persistent elevations of transaminases. Dose adjustment in renal impairment: consider reduced dosing in severe renal dysfunction. Drug interaction review: assess concomitant medications that affect CYP3A4 or cholesterol metabolism. Store at ambient temperature: keep tablets in the original container, protect from moisture and excessive heat.

Inegy interacts with several medicines; the nature of the interaction determines the required clinical action.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can markedly increase simvastatin exposure. - Gemfibrozil: raises risk of myopathy and rhabdomyolysis. - Niacin at high doses: potentiates muscle toxicity. - Cyclosporine: elevates both simvastatin and ezetimibe levels. - Antifungal agents (e.g., ketoconazole): significantly increase statin concentrations.

Moderate Interactions (Monitor Closely): - Amiodarone: may increase statin plasma levels modestly. - Warfarin: potential for altered anticoagulant effect. - Digoxin: slight increase in serum concentrations. - Grapefruit juice: can raise simvastatin exposure. - Antacids (e.g., aluminum hydroxide): may reduce ezetimibe absorption.